It’s a dream of medical science that looks tantalizingly within reach, the artificial pancreas, a potential breakthrough treatment for the scourge of type 1 diabetes.To see important ads, turn off your ad blocker! Article continued below:
Yes, the concept of an artificial pancreas has been a promising and exciting development in the field of medical science, particularly in the management of type 1 diabetes.
Type 1 diabetes is an autoimmune condition where the body’s immune system attacks and destroys the insulin-producing beta cells in the pancreas.
As a result, people with type 1 diabetes require insulin therapy to regulate their blood sugar levels.
The artificial pancreas, also known as a closed-loop system, aims to automate and improve the process of insulin delivery by combining a continuous glucose monitoring (CGM) system with an insulin pump.
Here’s how it typically works.
Continuous Glucose Monitoring (CGM): A sensor is placed under the skin to continuously monitor blood sugar levels. This sensor provides real-time data on glucose levels, allowing for better control and understanding of blood sugar fluctuations.
Pancreas and Insulin Pump.
An insulin pump is used to deliver insulin to the body. In a closed-loop system, the pump receives data from the CGM and adjusts insulin delivery accordingly.
The heart of the artificial pancreas is a control algorithm that analyzes the CGM data and determines the appropriate insulin infusion rate. It can adjust insulin delivery to prevent high or low blood sugar levels.
The key benefit of an artificial pancreas is that it can provide more precise and timely insulin delivery than manual injections or traditional insulin pumps. This can help people with type 1 diabetes achieve better blood sugar control and reduce the risk of complications associated with diabetes.
Research and development in this field have made significant strides, and there are already commercial artificial pancreas systems available for use by individuals with diabetes.
However, it’s essential to note that while these systems are a significant advancement, they may still require user intervention in certain situations, and careful monitoring is advised.
The development of the artificial pancreas represents a promising avenue for improving the quality of life for individuals with type 1 diabetes, and ongoing research continues to refine and enhance these systems to make them even more effective and user-friendly.
Meant to mimic the function of a real pancreas, the artificial version is a complex device that combines a pager-sized continuous glucose monitor and sensor that tracks blood sugar with a pump that automatically delivers the correct dose of insulin at just the right time.
Pancreas and technology.
That technology could make a major difference to the 3 million Americans with the disease who must vigilantly monitor their blood sugar, even at night, and risk deadly consequences if they are slow to notice a dangerous change.
But it is caught up in America’s long-running tug of war between supporters of more rapid medical innovation and those who seek better safety for new devices. A fresh confrontation is about to break open this week as the U.S.
Food and Drug Administration lays out a path toward regulatory approval for such devices.
Advocates of the artificial pancreas fear the bar will be set too high in terms of how the devices can be tested in patients, to what lengths companies will need to go to prove they are safe and whether a change in even one of its components will require a whole new round of testing.
People on both sides of the debate have a personal stake in the outcome.
Jeffrey Brewer, president and chief executive of the Juvenile Diabetes Research Foundation, a powerful advocacy group, has a teenage son with type 1 diabetes.
He notes that medical device giant Medtronic has a very early version of an artificial pancreas called the Paradigm Veo insulin pump, sold in 50 countries but not in the United States.
The pump has an automated safety feature, called low glucose suspend, that shuts off the insulin flow when glucose falls dangerously low.
The Veo, and newer devices being developed, are meant to be worn outside the body, but are connected to patients through a tiny catheter placed just under the skin.
That device could have prevented Brewer’s son from overdosing on insulin and spending two days in the hospital.
Brewer says cumbersome FDA regulations in June requiring proof of safety and effectiveness for low glucose suspend, already widely used elsewhere, will set back U.S. approval for at least 2-1/2 years.
He is worried the agency will take a similar approach when it issues final guidance, expected this week, on the more complex artificial pancreas.
Charles “Chip” Zimliki, who heads an FDA initiative to speed up availability of an artificial pancreas, defends the agency’s caution over a device on which many lives will depend. A type 1 diabetic himself, Zimliki says he wants to see these devices approved.
But the FDA has been sharply criticized for approving devices that proved unsafe, such as artificial hips recalled last year by Johnson & Johnson. The agency is unlikely to skip any steps to get a device as complicated as an artificial pancreas to patients.
Medtronic said it was not aware of any problems specifically related to its low glucose suspend feature. It said the devices have a high safety profile and that two dozen complaints would amount to one per 3,000 pumps.